Results 91 to 100 of about 11,407 (242)
Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite +3 more
wiley +1 more source
Factors that Influence Healthcare Professionals' Intentions towards Biosimilars
INNOVATIONS in PharmacyBackground: Physicians often prescribe original biologic products to patients who have not used them before and are reluctant to switch to biosimilars.
Mohammed Alqahtani +2 more
doaj +1 more source
Biosimilars in the management of neutropenia: focus on filgrastim
, 2016 Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria ...
Aricò M, Caselli D, Cesaro S
core
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
, 2018 The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, and ...
Kvien, TK +8 more
core +1 more source
Què són els medicaments biosimilars? [PDF]
, 2021 Medicaments biosimilars; Medicaments biològics; UtilitzacióMedicamentos biosimilares; Medicamentos biológicos; UtilizaciónBiosimilar medicines; Biological medicines; UseAquest article explica què són els medicaments biosimilars, quins tipus hi ha ...
Grup d'Informació sobre Medicaments Dirigida a la Ciutadania
core
Head &Neck, Volume 48, Issue 7, Page 1876-1884, July 2026.ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh +9 more
wiley +1 more source
, 2018 This presentation discusses the competition law issues raised by biosimilars. While many of the issues are similar to those raised by generics, the fact that, unlike generics, biosimilars are not exact copies of the original product means that the ...
Hull, David
core
Biosimilars Have Arrived: Rituximab
, 2018 A biosimilar is a biologic product that is highly similar to a licensed biologic (“originator”) such that there are no clinically meaningful differences in safety, purity, or potency between the biosimilar and the originator.
K. Lea Sewell +2 more
core +1 more source
Biosimilars in rheumatology: what the clinician should know
RMD Open, 2015 Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars ...
Jonathan Kay +3 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 1, Page 159-172, 1 July 2026.What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin +20 more
wiley +1 more source